[go: up one dir, main page]

RU2017134379A - Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 - Google Patents

Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 Download PDF

Info

Publication number
RU2017134379A
RU2017134379A RU2017134379A RU2017134379A RU2017134379A RU 2017134379 A RU2017134379 A RU 2017134379A RU 2017134379 A RU2017134379 A RU 2017134379A RU 2017134379 A RU2017134379 A RU 2017134379A RU 2017134379 A RU2017134379 A RU 2017134379A
Authority
RU
Russia
Prior art keywords
pyridin
cyano
methyl
methylurea
formyl
Prior art date
Application number
RU2017134379A
Other languages
English (en)
Inventor
Николь Бушманн
Робин Алек Фэрхерст
Паскаль Фюре
Томас КНЁПФЕЛЬ
Катрин Леблан
Роберт Мах
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2017134379A publication Critical patent/RU2017134379A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (60)

1. Соединение формулы (I) в свободной форме или в форме фармацевтически приемлемой соли
Figure 00000001
где
X представляет собой N или CH;
A представляет собой C(O) и B представляет собой NR5 или
A и B вместе образуют часть 5- или 6-членного ароматического кольца, где A представляет собой C и B представляет собой C или N;
R1 выбран из водорода, гидроксиС1-С3алкила, галогенС1-С3алкила, CO2H, CH2NR2R3, 5-членного ароматического гетероциклического кольца, содержащего по меньшей мере один гетероатом, выбранный из N, О или S, где кольцо необязательно замещено одним или более C1-C3алкилами;
R2 представляет собой C1-C3алкил и R3 представляет собой C(O)C1-C3алкил
или
R2 и R3 вместе с N, к которому они присоединены, образуют насыщенное 5- или 6-членное кольцо, необязательно содержащее один дополнительный гетероатом, выбранный из N, О или S, где это кольцо необязательно замещено одним или более R4;
R4 для каждого случая, независимо выбран из C1-C3алкила, C1-C3алкокси или два R4, присоединенные к одному и тому же углеродному атому, образуют оксогруппу;
R5 выбран из водорода, C1-C3алкила, C1-C3алкоксиC1-C3алкила, (CH2)0-1-R6;
R6 представляет собой 4-, 5- или 6-членное насыщенное гетероциклическое кольцо, содержащее по меньшей мере один гетероатом, выбранный из N, O или S;
R7 выбран из циано, галогенС1-С3алкила;
R8 выбран из водорода, NR9R10, C1-C6алкокси;
R9 представляет собой водород;
R10 выбран из C1-C6алкила, гидроксиC1-C6алкила, C1-C4алкоксиC1-C6алкила.
2. Соединение по п.1 формулы (Ia) в свободной форме или в форме фармацевтически приемлемой соли
Figure 00000002
3. Соединение по п.1 формулы (Ib) в свободной форме или в форме фармацевтически приемлемой соли
Figure 00000003
где n равно 0 или 1;
B представляет собой C или N;
D, E, F, G каждый независимо выбран из CH или N, при условии, что, когда n равно 0, по меньшей мере один из B, E, F или G представляет собой N.
4. Соединение по любому из пп.1-3 в свободной форме или в форме фармацевтически приемлемой соли, где X предствляет собой CH.
5. Соединение по п.1 в свободной форме или в форме фармацевтически приемлемой соли, которое выбрано из
6-((2-(6-формилпиридин-2-ил)фенил)амино)никотинонитрила;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формилпиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формилпиридин-2-ил)-1-(2-метоксиэтил)мочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формилпиридин-2-ил)-1-((тетрагидрофуран-3-ил)метил)мочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формил-5-(гидроксиметил)пиридин-2-ил)-1-((тетрагидрофуран-3-ил)метил)мочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(7-гидрокси-5-оксо-5,7-дигидрофуро[3,4-b]пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(7-гидрокси-5-оксо-5,7-дигидрофуро[3,4-b]пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-этил-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)мочевины;
3-(5-циано-4-(изопропиламино)пиридин-2-ил)-1-этил-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)мочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-этил-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)мочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-(изопропиламино)пиридин-2-ил)-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)-1-метилмочевины;
N-((6-(3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-метилуреидо)-2-формилпиридин-3-ил)метил)-N-метилацетамида;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(5-(дифторметил)-6-формилпиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(6-формил-5-((4-метилпиперазин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(5-(дифторметил)-6-формилпиридин-2-ил)-1-метилмочевины;
3-(5-цианопиридин-2-ил)-1-(6-формил-5-((2-оксопирролидин-1-ил)метил)пиридин-2-ил)-1-метилмочевины3-(5-цианопиридин-2-ил)-1-(6-формил-5-((2-оксопирролидин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формил-5-((2-оксопирролидин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(6-формил-5-((4-метил-2-оксопиперазин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-((2-гидрокси-2-метилпропил)амино)пиридин-2-ил)-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(6-формил-5-((2-оксопирролидин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-1-(6-формил-5-((4-метил-2-оксопиперазин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(6-формил-5-(1-метил-1H-пиразол-4-ил)пиридин-2-ил)-1-метилмочевины;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(6-формил-5-((3-метоксипирролидин-1-ил)метил)пиридин-2-ил)-1-метилмочевины;
6-(2-((4-((2-метоксиэтил)амино)-5-(трифторметил)пиридин-2-ил)амино)-1H-имидазол-1-ил)-3-(1-метил-1H-пиразол-4-ил)пиколинальдегида;
6-(5-((4-((2-метоксиэтил)амино)-5-(трифторметил)пиридин-2-ил)амино)-1H-пиразол-1-ил)-3-(1-метил-1H-пиразол-4-ил)пиколинальдегида;
3-(5-циано-4-изопропоксипиридин-2-ил)-1-(6-формил-5-(пирролидин-1-илметил)пиридин-2-ил)-1-метилмочевины и
1-(5-циано-4-изопропоксипиридин-2-ил)-3-(4-формилпиримидин-2-ил)мочевины.
6. Фармацевтическая композиция, содержащая терапевтически эффективное количество соединения по любому из пп.1-5 или его фармацевтически приемлемой соли и один или несколько фармацевтически приемлемых носителей.
7. Комбинация, содержащая терапевтически эффективное количество соединения по любому из пп.1-5 или его фармацевтически приемлемой соли и одно или несколько терапевтически активных средств.
8. Соединение по любому из пп.1-5 или его фармацевтически приемлемая соль для применения в качестве лекарственного средства.
9. Соединение по любому из пп.1-5 или его фармацевтически приемлемая соль для применения при лечении рака.
10. Соединение по п.9 или его фармацевтически приемлемая соль, где рак выбран из рака печени, рака молочной железы, глиобластомы, рака предстательной железы, рабдомиосаркомы, рака желудка, рака яичников, рака легких, рака толстой кишки.
11. Применение соединения по любому из пп.1-6 или его фармацевтически приемлемой соли в изготовлении лекарственного средства для лечения рака.
RU2017134379A 2015-03-25 2016-03-23 Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 RU2017134379A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160735.5 2015-03-25
EP15160735 2015-03-25
PCT/IB2016/051631 WO2016151499A1 (en) 2015-03-25 2016-03-23 Formylated n-heterocyclic derivatives as fgfr4 inhibitors

Publications (1)

Publication Number Publication Date
RU2017134379A true RU2017134379A (ru) 2019-04-03

Family

ID=52706082

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134379A RU2017134379A (ru) 2015-03-25 2016-03-23 Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4

Country Status (11)

Country Link
US (2) US10189813B2 (ru)
EP (1) EP3274344B1 (ru)
JP (1) JP6695353B2 (ru)
KR (1) KR20170129757A (ru)
CN (1) CN107667092B (ru)
AU (1) AU2016238436A1 (ru)
BR (1) BR112017016817A2 (ru)
CA (1) CA2976766A1 (ru)
MX (1) MX2017012295A (ru)
RU (1) RU2017134379A (ru)
WO (1) WO2016151499A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384034B (es) 2015-12-17 2025-03-14 Eisai R&D Man Co Ltd Agente terapeutico para cancer de mama.
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2019024876A1 (zh) * 2017-08-04 2019-02-07 上海和誉生物医药科技有限公司 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物
TW202112379A (zh) * 2019-06-05 2021-04-01 美商亞瑟尼克斯公司 治療及／或預防乾癬之方法
CN110563704A (zh) * 2019-09-23 2019-12-13 南京工业大学 基于四氢键和配位键协同作用组装的四面体笼及制备方法
CN112255344B (zh) * 2020-10-19 2022-10-28 陕西科技大学 一种超高效液相色谱串联质谱鉴别不同年份白酒的方法
CN112279834B (zh) * 2020-12-29 2021-04-09 北京鑫开元医药科技有限公司 一种fgfr4抑制剂、制备方法、药物组合物及其应用
CN115166073B (zh) * 2022-06-21 2023-06-13 北京泰德制药股份有限公司 一种伊沙佐米或其盐异构体的检测方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
KR100609800B1 (ko) 1998-12-16 2006-08-09 워너-램버트 캄파니 엘엘씨 Ｍｅｋ 저해제를 사용한 관절염 치료 방법
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
IL163748A0 (en) 2002-03-05 2005-12-18 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
IL163711A0 (en) 2002-03-08 2005-12-18 Eisai Co Ltd Macrocyclic compounds useful as pharmaceuticals
SI2275102T1 (sl) 2002-03-13 2015-12-31 Array Biopharma, Inc. N3 alkilirani benzimidazol derivati kot MEK inhibitorji
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
WO2004037808A1 (en) * 2002-10-24 2004-05-06 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CA2762955A1 (en) * 2003-10-16 2005-04-28 Imclone Llc Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN102964294A (zh) 2004-09-02 2013-03-13 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007136893A2 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
WO2009009173A2 (en) 2007-04-02 2009-01-15 Genentech, Inc. Klotho beta
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102224170A (zh) 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
CN102030742B (zh) * 2009-09-28 2013-06-19 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
CN102596916B (zh) * 2009-10-30 2015-06-17 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
HUE055502T2 (hu) 2012-07-11 2021-11-29 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途

Also Published As

Publication number Publication date
WO2016151499A1 (en) 2016-09-29
CN107667092B (zh) 2021-05-28
MX2017012295A (es) 2018-01-09
US20190105309A1 (en) 2019-04-11
US20180065951A1 (en) 2018-03-08
JP2018509442A (ja) 2018-04-05
EP3274344B1 (en) 2019-04-24
JP6695353B2 (ja) 2020-05-20
CN107667092A (zh) 2018-02-06
BR112017016817A2 (pt) 2018-04-03
EP3274344A1 (en) 2018-01-31
CA2976766A1 (en) 2016-09-29
US10189813B2 (en) 2019-01-29
US10786492B2 (en) 2020-09-29
AU2016238436A1 (en) 2017-08-17
KR20170129757A (ko) 2017-11-27

Similar Documents

Publication Publication Date Title
RU2017134379A (ru) Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
HRP20180382T1 (hr) Inhibitori protein kinaze
ME02125B (me) Inhibitori protein apoptoze (iap)
RU2013141413A (ru) Производные изоксазолина для борьбы с беспозвоночными паразитами
JP2016513660A5 (ru)
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
JP2020503299A5 (ru)
JP2016517878A5 (ru)
NZ609955A (en) Sgc stimulators
JP2017532360A5 (ru)
JP2009538897A5 (ru)
JP2017530999A5 (ru)
JP2014505089A5 (ru)
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2017502940A5 (ru)
HRP20130861T1 (hr) 1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma
JP2012528166A5 (ru)
RU2016136116A (ru) Фармацевтические соединения
RU2009116818A (ru) Ингибиторы протеинкиназ и способы их применения
RU2016129953A (ru) Фармацевтические комбинации
NZ717119A (en) Aryl-or heteroaryl-substituted benzene compounds
JP2015531366A5 (ru)
JP2014511869A5 (ru)
HRP20140919T1 (hr) Spojevi koji moduliraju androgene receptore

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20201005